Access is especially inconsistent when it comes to advanced therapy medicinal products (ATMPs), which often require specialized handling and delivery systems. Patients in Greece are facing some of the longest delays in Europe when it comes to accessing newly approved medicines, with the average wait time now stretching to 654 days. This striking figure, revealed in new data from the European Federation of Pharmaceutical Industries and Associations (EFPIA), highlights deep-rooted structural issues in the Greek healthcare and regulatory system that continue to hamper timely access to innovative treatments. Two recent reports-the WAIT Indicator and a detailed analysis by the CRA on the causes of medicine unavailability-underscore the challenges European countries face in ensuring equal access to pharmaceutical innovation. The WAIT Indicator, which tracked 173 new medicines approved between 2020 and 2023, found that across the European...